Currently, there are 34.67M common shares owned by the public and among those 16.72M shares have been available to trade.
The company’s stock has a 5-day price change of 9.32% and 12.17% over the past three months. IGMS shares are trading -80.48% year to date (YTD), with the 12-month market performance down to -78.89% lower. It has a 12-month low price of $0.92 and touched a high of $22.50 over the same period. IGMS has an average intraday trading volume of 212.80K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.69%, 3.99%, and -77.66% respectively.
Institutional ownership of IGM Biosciences Inc (NASDAQ: IGMS) shares accounts for 21.92% of the company’s 34.67M shares outstanding.
It has a market capitalization of $77.55M and a beta (3y monthly) value of 0.48. The earnings-per-share (ttm) stands at -$3.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.54% over the week and 6.58% over the month.
Earnings per share for the fiscal year are expected to increase by 59.57%, and 59.54% over the next financial year. EPS should grow at an annualized rate of 45.66% over the next five years, compared to 7.57% over the past 5-year period.
Looking at the support for the IGMS, a number of firms have released research notes about the stock. Stifel stated their Hold rating for the stock in a research note on January 10, 2025, with the firm’s price target at $27-$2.50. RBC Capital Mkts coverage for the IGM Biosciences Inc (IGMS) stock in a research note released on January 10, 2025 offered a Sector Perform rating with a price target of $1.50. BMO Capital Markets on their part issued Market Perform rating on January 10, 2025.
